Get Free Trial
News & Analysis
On The Fly
About The Fly
Instant updates and real-time market news.
Nabriva Therapeutics reports Q3 EPS (90c), consensus (29c)
Reports Q3 revenue $1.468M, consensus $2.3M.
Nabriva Therapeutics valuation 'hard to resist,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen says she left meetings with Nabriva Therapeutics management even more convinced that the market opportunity for lefamulin is underappreciated. Nabriva Therapeutics shares have been weak since the company announced positive data from its second Phase 3 study, Chen tells investors in a research note titled "NBRV Hard to Resist At Its Current Valuation." She sees no fundamental reason for the weakness and keeps an Overweight rating on the shares with a $16 price target.
Nabriva Therapeutics initiated with an Outperform at Northland
Northland initiated Nabriva Therapeutics with an Outperform and $17.50 price target.
Nabriva Therapeutics price target lowered to $5 from $9 at BofA/Merrill
BofA/Merrill analyst Jason Gerberry lowered his price target on Nabriva Therapeutics to $5, citing his lower expected probability of success of 60% vs. 75% prior in its recently acquired CONTEPO for complicated urinary tract infection. The analyst says the program's main risk is an "imbalance of liver enzyme elevation while a slightly higher dose reduces read -through from about a 45-year post-market EU safety". Gerberry now believes that CONTEPO is a "niche opportunity", and lowers his peak sales view to $50M from $80M prior. The analyst also keeps his Buy rating on Nabriva on valuation as well as the opportunity for its two FDA action dates for lefamulin and CONTEPO in the second half of 2019.
Nabriva Therapeutics resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz resumed coverage of Nabriva Therapeutics with an Overweight rating and a $8 price target, stating that its "first-in-class" antibiotics lefamulin and Contepo both have approvable Phase 3 data. He believes at current levels Nabriva shares are pricing in a "worst case scenario" for both antibiotics, but he sees it as likely that Nabriva exceeds the low expectations. Lebowitz forecasts risk-adjusted 2025 sales for lefamulin and Contepo of $228M and $33M, respectively.
TODAY'S FREE FLY STORIES